Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Petrylak, 2004, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, 351, 1513, 10.1056/NEJMoa041318 Tannock, 2004, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, 1502, 10.1056/NEJMoa040720 Beer, 2014, Enzalutamide in metastatic prostate cancer before chemotherapy, N Engl J Med, 371, 424, 10.1056/NEJMoa1405095 de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618 Fizazi, 2012, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 13, 983, 10.1016/S1470-2045(12)70379-0 Kantoff, 2010, Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N Engl J Med, 363, 411, 10.1056/NEJMoa1001294 Parker, 2013, Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med, 369, 213, 10.1056/NEJMoa1213755 Rathkopf, 2014, Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302), Eur Urol, 10.1016/j.eururo.2014.02.056 Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096 Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506 Basch, 2013, Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial, Lancet Oncol, 14, 1193, 10.1016/S1470-2045(13)70424-8 Kalbfleisch, 2002 Branson, 2002, Estimating a treatment effect in survival studies in which patients switch treatment, Stat Med, 21, 2449, 10.1002/sim.1219 Kluetz, 2013, Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary, Clin Cancer Res, 19, 6650, 10.1158/1078-0432.CCR-13-2134 Morris MJ, Molina A, Small EJ, et al. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol (in press). Fizazi, 2014, Does Gleason score predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase 3 trials, Proc Am Soc Clin Oncol, 32 Bellmunt, 2013, Impact of prior antiandrogen exposure on clinical outcomes in patients receiving abiraterone acetate: results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer post-docetaxel, Ann Oncol, 24 Al Nakouzi, 2014, Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies, Eur Urol Pezaro, 2014, Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents, Eur Urol, 66, 459, 10.1016/j.eururo.2013.11.044 Engel-Nitz, 2011, Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population, Cancer Manag Res, 3, 233 Harris, 2011, A population-based study of prostate cancer chemotherapy, Clin Oncol (R Coll Radiol), 23, 706, 10.1016/j.clon.2011.04.014 Antonarakis, 2014, AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer, N Engl J Med, 371, 1028, 10.1056/NEJMoa1315815